ARE-PROTACs Enable Co-degradation of an Nrf2-MafG Heterodimer.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01909
Abstract: Proteolysis-targeting chimera (PROTAC) technology has emerged as a potential strategy to degrade "undruggable" proteins in recent years. Nrf2, an aberrantly activated transcription factor in cancer, is generally considered undruggable as lacking active sites or allosteric… read more here.
Keywords: nrf2 mafg; degradation; mafg heterodimer; nrf2 ... See more keywords